Morning Star analyst Kai Wang said in a report that JD Health's growth momentum is surpassing that of its peers, thanks to its partnerships with many global pharmaceutical giants, including Eli Lilly. The company's third-quarter revenue increased 29% year over year. Wang said JD Health benefits from its advantages in logistics and user acquisition. He said its expanding product portfolio could have a network effect, and partnerships with major pharmaceutical companies will help in this. Wang added, “We are optimistic about JD Health because it has a narrow moat and think the stock price pullback may provide an attractive entry point. “Morningstar maintained a reasonable valuation of HK$58.00 as revenue for the third quarter was in line with the company's expectations. The stock's latest report was HK$58.30.

Morning Star analyst Kai Wang said in a report that JD Health's growth momentum is surpassing that of its peers, thanks to its partnerships with many global pharmaceutical giants, including Eli Lilly. The company's third-quarter revenue increased 29% year over year. Wang said JD Health benefits from its advantages in logistics and user acquisition. He said its expanding product portfolio could have a network effect, and partnerships with major pharmaceutical companies will help in this. Wang added, “We are optimistic about JD Health because it has a narrow moat and think the stock price pullback may provide an attractive entry point. “Morningstar maintained a reasonable valuation of HK$58.00 as revenue for the third quarter was in line with the company's expectations. The stock's latest report was HK$58.30.